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ABSTRACT 
Niosomes represent a promising drug delivery module. Noisome same as to liposome and Noisome represent alternative vesicular 
drug delivery systems with respect to liposomes, due to the noisome ability to encapsulate the different type of drugs within  their 
multi environmental structure. Niosomes are thoughts to be a better system for drug delivery as compared to liposomes due to  
various factors like cost, stability etc. They are many types of drug deliveries that can be possible using niosomes like tar geting, 
ophthalmic, topical, parenteral, etc. In recent research, comprehensive research carried over noisome as a drug carrier. Vari ous drugs 
are enlisted and tried in noisome surfactant vesicles. Niosomes proved to better drug carrier system and has the poten tial to reduce 
the side effects of drugs and increased therapeutic effectiveness in various diseases. Noisome used more than fifty drugs are  tried in 
niosomal formulations by the intravenous route, per oral administration, trans -dermal route of administration, and inhalation 
preparation, ocular nasal route of administration. Treatment of infectious diseases and immunization has undergone a revoluti onary 
work in recent years. The large numbers of disease -specific biological have been developed, and also emphasis has been made to 
effectively deliver these biological. Niosomes shows an emerging class of novel vesicular systems. Niosomes are self -assembled 
vesicles composed primarily of synthetic surfactant and cholesterol. Comprehensive research carried over no isome as a drug carrier. 
Various drugs are enlisted and tried in noisome surfactant vesicles. This article presents an overview of the techniques of p reparation 
of noisome, types of noisome, characterization and their applications.  
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Niosomes are a novel drug delivery system, which 
entrapped the hydrophilic drug in the core cavity and 
hydrophobic drugs in the non-polar region present 
within the bilayer hence both hydrophilic and 
hydrophobic drugs can be incorporated into niosomes [1]. 
The niosomes are amphiphilic in nature, in which the 
medication is encapsulated in a vesicle which is made by 
nonionic surfactant and hence the name niosomes. The 
niosomes size is very small and microscopic [2]. The first 
niosome formulations were developed and patented by 
L’Oréal in 1975. In the presence of proper mixtures of 
surfactants and charge inducing agents from the 
thermodynamically stable vesicles. Niosomes are mostly 
studied as an alternative to liposomes because they 
alleviate the disadvantages associated with liposomes [3]. 
Niosomes overcome the disadvantages associated with 
liposomes such as chemical instability. The chemical 
instability of liposomes is due to their predisposition to 
oxidative degradation and variable purity of 
phospholipids. The main purpose of developing a 
niosomal system is chemical stability, biodegradability, 
biocompatibility, chemical stability, low production cost, 
easy storage and handling, and low toxicity [4, 5]. 
Niosomes can be administrated through various routes 
such as oral, parental, topical. Niosomes are used as a 
system to deliver different types of drugs such as 
synthetic and herbal, antigens, hormones, and other bio-
active compounds [6, 7, and 8]. This article presents some 
features of niosomes along with an overview of the 
preparation techniques and the current formulations of 
niosomes are encapsulation for the delivery of bio-active 
compounds. 
SALIENT FEATURES OF NIOSOMES: [2, 9, AND 10] 
 Niosomes can entrap solutes.  
 Niosomes are osmotically active and stable.  
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 Niosomes have an infra-structure comprising of 
hydrophobic and hydrophilic for the most part 
together thus likewise oblige the medication atoms 
with an extensive variety of dissolvability. 
 Niosome discharge the medication in a controlled 
manner by means of its bilayer which gives 
supported the arrival of the encased medication, so 
niosomes fill in as medication warehouse in the 
body.  
 Targeted medication conveyance can likewise be 
accomplished utilizing niosomes the medication is 
conveyed specifically to the body part where the 
remedial impact is required. Thereby lessening the 
measurement required to be managed to 
accomplish the coveted impact.  
 They improve the solubility and oral bioavailability 
of poorly soluble drugs and enhance the skin 
permeability of drugs when applied topically.  
  Niosomes exhibits flexibility in their structural 
character (composition, fluidity, and size) and can 
be designed according to the desired situation.  
 Niosomes can improve the performance of the site 
of action of the drug.   
 Better availability to the particular site of action, 
just by protecting the drug from a biological 
environment.   
 Niosomes increase the stability of the entrapped 
drug in some manner. 
ADVANTAGES: [6, 11] 
1. Bioavailability Improvement: The term 
bioavailability alludes to the part of a dosage that is 
accessible at the site of activity in the body. 
Niosomes have unmistakable preferences over 
regular plans since the vesicles can go about as 
medication stores and shields sedate from acidic 
and enzymatic debasement in the gastrointestinal 
tract which brings about bioavailability 
improvement and furthermore expanded the 
capacity to cross the anatomical hindrance of the 
gastrointestinal tract.  
2. They enhance the restorative execution of the 
medication particles by postponed leeway from the 
dissemination, shielding the medication from the 
natural conditions and limiting impacts to target 
cells. 
3. Niosomal dispersion in an aqueous system can is 
emulsified in a non-aqueous system to regulate the 
delivery.  
4. Rate of drug and administer normal vesicle in the 
external non-aqueous phase.  
5. They are osmotically active and stable, as well as 
increase the stability of the entrapped drug.  
6. Handling and storage of surfactants require no 
special conditions.  
7. They can improve the oral bioavailability of poorly 
absorbed drugs and enhance skin penetration of 
drugs. 
8. They can be made to reach the site of action of the 
system by oral, parenteral as well as topical routes. 
COMPARISON OF LIPOSOMES AND NIOSOMES: [11-13]  
In spite of the fact that the liposomes and niosomes are 
practically same, both can be utilized as a part of focused and 
managed sedate conveyance framework, property of both 
relies on structure of the bilayer and strategies for their 
planning and both increment bioavailability and abatement 
the body leeway. Niosomes are prepared from uncharged 
single-chain surfactant and cholesterol whereas liposomes 
are prepared from double chain phospholipids, he major 
differences between liposomes and niosomes are described 
as follows, (Table 1, Figure 1) 
 
Figure 1: Structure of Niosome. 
Table 1: Differences between Liposomes and Niosomes.
 
Sr.no. Liposomes Niosomes 
1 More expensive Less expensive 
2 Phospholipids are prone to oxidative Degradation. But non-ionic surfactants are stable toward this. 
3 
Required special method for storage, handling and 
purification of phospholipids. 
No special methods are required for such 
formulations Comparatively. 
4 Phospholipids may be neutral charged. Non-ionic surfactants are uncharged. 
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Types of Niosomes:[2,4] 
Bola surfactant-containing niosomes:  
Bola surfactant-containing niosomes the surfactant used 
in Bola surfactant-containing niosomes are made of 
omega hexadecylbis-(1-aza-18 crown-6) (bola 
surfactant): span- 80/cholesterol in 2:3:1molar ratio.  
Proniosomes:  
Proniosomes is made from the carrier and surfactant 
mixture. After the hydration of proniosomes, Niosomes 
are produced.  
Aspasomes:  
Aspasomes is produced using the mix of 
acorbylpalmitate, cholesterol, and exceptionally charged 
lipid diacetyl phosphate prompts the arrangement of 
vesicles. Aspasomes are first hydrated with water/fluid 
arrangement and afterward, it is subjected to sonication 
to get the niosomes. Aspasomes can be utilized to build 
the transdermal saturation of medications. Aspasomes 
have likewise been utilized to diminish scatter caused by 
responsive oxygen species as it has innate cell 
reinforcement properties.  
Niosomes in carbopol gel: 
Niosomes were prepared from drug, spans, and 
cholesterol than it is incorporated in carbopol-934 gel 
(1%w/w) base containing propylene glycol (10% w/w) 
and glycerol (30% w/w). 
Vesicles in water and oil system (v/w/o):   
In this strategy, the aqueous niosomes into an oil stage 
frame vesicle in water in oil emulsion (v/w/o). This can 
be set up by the expansion of niosomes suspension 
figured from a blend of sorbitol monostearate, 
cholesterol and solulan C24 (Poly-24-Oxyethylene 
cholesteryl ether) to the oil stage at 60℃.This results in 
the formation of vesicle in water in oil (v/w/o) emulsion 
which by cooling to room temperature for the 
formulation vesicle in water in oil gel (v/w/o gel). The 
v/w/o gel thus obtained can entrapped proteins/ 
proteinous drugs and also protect it from enzymatic 
degradation after oral administration and controlled 
release.  
Niosomes of hydroxyl propyl methylcellulose:  
In this type, a base containing 10% glycerin of hydroxyl 
propyl methylcellulose was first prepared and then 
niosomes were incorporated in it. 
Deformable niosomes:  
The mixture of non-ionic surfactants, ethanol, and water 
forms the deformable niosomes. These are smaller 
vesicles and easily pass through the pores of stratum 
corneum, which leads to increase penetration efficiency. 
It can be used in topical preparation [15, 16] 
The niosomes are classified according to the number 
and size of bilayer which is as follows,  
i) Multi Lamellar Vesicles (MLV): Multilamellar vesicles 
are the most widely used niosomes. It consists of a 
number of bilayers. The approximate size of the vesicles 
is 0.5-10 μm diameter. It is simple to formulate and is 
mechanically stable upon storage for long periods.  
ii) Large Unilamellar Vesicles (LUV): These are the 
large unilamellar vesicles which having a high 
aqueous/lipid compartment ratio so that larger volumes 
of bio-active materials can be entrapped.  
iii) Small Unilamellar Vesicles (SUV):  These small 
unilamellar vesicles are prepared from multilamellar 
vesicles by sonication method, French press and 
extrusion method. 
Components of Niosomes:  
The two major components utilized for the readiness of 
niosomes are Cholesterol and Nonionic surfactants. 
Cholesterol is utilized to give unbending nature and 
appropriate shape, adaptation to the niosomes. The part 
surfactants assume a noteworthy part in the 
development of niosomes. The accompanying non-ionic 
surfactants are for the most part utilized for the 
arrangement of niosomes the spans (span 
60,40,20,85,80), tweens (tween 20,40,60,80) and (Brij 
30,35,52,58,72,76).  
Cholesterol [9]  
Cholesterol is an amphiphilic nature; and it orients its OH 
group towards aqueous phase and aliphatic chain 
towards surfactant’s hydrocarbon chain. Cholesterol a 
waxy steroid metabolite is usually added to the non-ionic 
surfactants to provide rigidity Cholesterol is also prevent 
leakage by abolishing gel to liquid phase transition.  
Non-ionic surfactants [9,17]  
Niosomes are non-ionic surfactant unilamellar or 
multilamellar vesicles formed from synthetic non-ionic 
surfactants. Non-ionic surfactant possesses hydrophilic 
head group and a hydrophobic tail. As HLB value 
increases, therefore, alkyl chain increases the size of 
niosome increases. Formulation of niosome is not 
suitable on the HLB value 14-17. HLB values 8 have the 
highest entrapment efficiency. Nonionic surfactants are 
as follows, Ether linked surfactant: These are surfactants 
contain hydrophilic and hydrophobic moieties which are 
linked by ether, polyoxyethylene alkyl ethers with the 
general formula (CnEOm), where n; i.e. the number of 
carbon atoms vary between 12 and 18 and m; i.e. the 
number of oxyethylene unit varies between 3 and 7.  
Di-alkyl chain surfactant:  
Surfactant was used as a principal component of 
niosomal preparation of stibogluconate and its potential 
in delivering sodium stibogluconate in experimental 
marine visceral leishmaniasis has been explored.  
C16H33CH-O [-CH2-CH-O] 7-H  
| |  
CH2CH2OH  
| 
C12H25-O        (mol. Wt. 972) 
 
Ester linked: These surfactants have ester linkage 
between hydrophilic and hydrophobic groups; hence it is 
also called as Ester linked surfactants.  
C15H31CO [O-CH2-CH-CH2]2-OH  
| 
OH       (mol. Wt. 393)   
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This surfactant also used in the preparation of 
stibogluconate bear the niosomes drug delivery and 
delivery the sodium stibogluconate to the experimental 
marine visceral leishmaniasis.  
Sorbitan esters:  
These are the ester-linked surfactants. The commercial 
sorbitan esters are prepared by the mixtures of the 
partial esters of sorbital and its mono and di-anhydrides 












Where R is H or an alkyl chain. These have been used to 
entrap a wide range of drugs viz doxorubicin. Fatty acid 
and amino acid compounds:  
Long-chain fatty acids and amino acid moieties have also 
been used in niosomes preparation which forms 
“Ufasomes” vesicles.  
Charge inducers: 
There are two types of charged inducers such as Positive 
and Negative charge inducers. It increases the stability of 
the vesicles by induction of charge on the surface of the 
prepared vesicles. It acts by preventing the fusion of 
vesicles due to repulsive forces of the same charge and 
provide higher values of zeta potential. The commonly 
used positive charge inducers are stearylamine and 
cetylpyridinium chloride and negative charge inducers 
are dicetyl phosphates, dihexadecyl phosphate and 
lipoamide acid. [9] 
Method of Preparation: 
Ether injection- [18] 
In this method, the slow injection of surfactant: cholesterol 
(150micro.mol.) in 20ml ether through a 14 gauze needle 
(25ml/ min.) in preheated 4ml aqueous phase maintained at 
600c. The ether the solution was evaporated using rotary 
evaporator, after evaporation of the organic solvent forms 
single-layered vesicles. 
Sonication: [19] 
Niosomes using the sonication method were prepared by 
Baillieet al 1986. In this method, surfactant: cholesterol 
(150micro.mol.)The mixture was dispersed in a 2ml aqueous 
phase in the vial. The dispersion is subjected to probe 
sonication for 3 min. at 600c.This method involved the 
formation of MLVs which are subjected to ultrasonic 
vibration. Sonicator is two type Probe and Bath sonicator. 
Probe sonicator is use when sample volume is small and Bath 
sonicator is used when sampling volume is large. 
 
Hand shaking method: [19] 
In this method, surfactant: cholesterol (150micro.mol.) 
mixture was dissolved in 10ml diethyl ether in RBF. The 
ether is evaporated under vacuum at room temperature in 
rotary evaporated. Upon hydration, the surfactant swells and 
is peeled off the support into a film. Swollen amphiphiles 
eventually fold to form vesicles. The liquid volume entrapped 
in vesicles appears to be small which 5-10% is. 
Extrusion method: [19] 
In this method, niosomes were prepared using C16G2, a 
chemically defined non -ionic surfactant by extrusion 
through a polycarbonate membrane. These studies not only 
demonstrate the effect of the number of extrusion on vesicles 
size but also the effect of size on encapsulation of drug. 
Reverse phase evaporation technique: [18, 19] 
In this method, the surfactant is dissolved in chloroform and 
added into the 0.25 volume phosphate saline buffer solution 
is emulsified to get w/o emulsion. The mixture is then 
solicited and subsequently, chloroform is evaporated under 
reduced pressure. The lipid or surfactant forms a gel first 
and subsequently hydrates to form vesicles. 
Bubble method: [6, 18] 
It is a novel technique for the one-step preparation of 
liposomes and niosomes without the use of organic solvents. 
It consists of the round-bottomed flask with three necks 
placed in a water bath to control the temperature. Water-
cooled reflux and thermometer are positioned in the first 
neck and second neck and nitrogen supply through the third 
neck. Cholesterol and surfactant are mixed together in this 
buffer (pH7.4) at 70°c. A continuous stream of nitrogen gas 
bubbles is generated and introduced through the dispersion 
process and produce a niosomes. 
Micro fluidization method [20] 
Micro fluidization is a current strategy to plan unilamellar 
vesicles of characterized estimate circulation. Based on the 
submerged jet principle, in this strategy, two fluidized 
streams connect at ultrahigh speeds, incorrectly 
characterized smaller-scale channels inside the interaction 
chamber. The impingement of thin liquid sheet along a 
common front is arranged in such a way that the energy 
supplied to the system remains within the area of niosomes 
formation. The outcome is a more prominent consistency, 
smaller size and better reproducibility of niosomes shaped. 
Separation of unentrapped drug [21-27] 
The separation of unentrapped solute from the vesicles can 
be done by various techniques, such as dialysis, gel filtration 
and Centrifugation. 
(i) Dialysis: Dialysis is one of the most important techniques 
used for removal of unentrapped drug from vesicles. In this 
technique, the aqueous niosomal dispersion is filled in 
dialysis tubing against phosphate buffer or normal saline or 
glucose solution. 
(ii) Gel Filtration: In this technique, the unentrapped drug is 
separated by gel filtration of niosomal dispersion through a 
Sephadex-G-50 column and elution with phosphate-buffered 
saline or normal saline. 
(iii) Centrifugation: The niosomal suspension is centrifuged 
and the supernatant is separated. The pellet is washed and 
then resuspended to obtain a niosomal suspension solution 
free from unentrapped drug [26,28]. 
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Factors Affecting Physico-chemical Properties of 
Niosomes: 
Various factors that affect the physico-chemical properties of 
niosomes are discussed further. 
Amount and type of surfactant [29] 
The mean size of niosomes increases proportionally with an 
increase in the HLB values of surfactants like Span 85 (HLB 
1.8) to Span 20 (HLB 8.6) because of the surface free energy 
decreases with an increase in hydrophobicity of surfactant. 
The bilayers of the vesicles are either in the supposed fluid 
state or in a gel state, contingent upon the temperature, the 
kind of lipid or surfactant and the nearness of different 
segments, for example, cholesterol. In the gel state, alkyl 
chains are available in an all-around requested structure, and 
in the fluid express, the structure of the bilayers is more 
confused. The surfactants and lipids are portrayed by the gel-
fluid stage change temperature (TC). Phase transition 
temperature (TC) of surfactant also affects entrapment 
efficiency i.e. Span 60 having higher TC, provides better 
entrapment. 
Nature of Surfactants [29] 
A surfactant utilized for the readiness of niosomes must have 
a hydrophilic head and hydrophobic tail. The hydrophobic 
tail may comprise of maybe a couple of alkyl or per-fluoro-
alkyl gatherings or now and again a solitary steroidal 
gathering. The hydrophobic tail of ether sort surfactants with 
single-chain alkyl is more poisonous than comparing the 
dialkyl ether chain. The ester type surfactants are chemically 
less stable than the ether type surfactants and the former is 
less toxic in nature than latter due to ester-linked surfactant 
degraded by esterase’s to triglycerides and fatty acid. The 
surfactants with an alkyl chain length from Carbon-12-
Carbon-18 are suitable for the preparation of niosomes. 
Surfactants such as C16EO5 (poly-oxyethylene-cetyl ether) or 
C18EO5 (polyoxyethylene stearyl ether) are used for the 
preparation of polyhedral vesicles. Span series surfactants 
having HLB number of between 4 and 8 can form vesicles. 
Nature of encapsulated drug: [30] 
The physical-synthetic properties of the typified medicate 
impact charge and the unbending nature of the niosome 
bilayer. The medication cooperates with surfactant head 
gatherings and builds up the charge that makes shared 
aversion between surfactant bilayers and subsequently 
expands vesicle estimate. The aggregation of vesicles is 
prevented due to the charge development on the bilayer. In 
Polyoxyethylene Glycol (PEG) coated vesicles; entrapped 
some drug is in the long PEG chains, thus reducing the 
tendency to increase the size. The hydrophilic-lipophilic 
balance of the drug affects the degree of entrapment. 
Structure of surfactants: [31] 
The geometry of vesicle to be shaped from surfactants is 
influenced by surfactant’s structure, which can be 
characterized by basic pressing parameters. The geometry of 
vesicle to be shaped can be predicated on the premise of 
basic pressing parameters of surfactants. Critical packing 
parameters can be defined using the following equation, 
CPP (Critical Packing Parameters) =V/lc × a0 
Where, 
V = hydrophobic group volume, 
lc = the critical hydrophobic group length, 
a0= the area of the hydrophilic head group 
Critical packing parameter value type of micellar structure 
formed can be ascertained as given below, 
If CPP < ½ formation of spherical micelles, 
If ½ < CPP < 1 formation of bilayer micelles product, 
If CPP > 1 formation inverted micelles. 
The temperature of hydration: [30] 
Hydration temperature influences the shape and size of the 
niosome, the temperature change of the niosomal system 
affects the assembly of surfactants into vesicles by which 
induces vesicle shape transformation. Ideally, the hydration 
temperature for noisome formation should be above the gel 
to the liquid phase transition temperature of the system. 
Resistance to osmotic stress: [8] 
Adding of a hypertonic salt solution to a suspension of 
niosomes brings about reduction in diameter. In hypotonic 
salt solution, there is initial slow release with a slight 
swelling of vesicles probably due to inhibiting of eluting fluid 
from vesicles, followed by faster release, which may be due 
to mechanical loosening process  of vesicles structure under 
osmotic stress. 
Evaluation: [2, 8, 29, 30]  
Entrapment efficiency: after preparing niosomal 
dispersion, the unentrapped drug is separated by dialysis 
centrifugation and gel filtration. The drug remains 
entrapped in niosomes s determined by complete vesicle 
disrupting using 50% n-propanol or 0.1% Triton X-100 
and analyzed resultant solution by appropriate assay 
method using the following equation. 
                         
                 
              
     
Bilayer Formation:  
Assembly of non-ionic surfactants to form a bilayer 
vesicle is characterized by an X-cross formation under 
light polarization microscopy.  
Size: The shape of niosomal vesicles is assumed to be 
spherical, and their mean diameter can be determined by 
laser light scattering method. Also, the diameter of these 
vesicles can be determined by using electron microscopy, 
molecular sieve chromatography, ultracentrifugation, 
photon correlation microscopy, optical microscopy and 
freeze-fracture electron microscopy.  
Numbers of lamellae:  
This is determined by using Nuclear Magnetic Resonance 
(NMR) spectroscopy, small-angle X-ray scattering, and 
electron microscopy.  
Membrane rigidity:  
Membrane rigidity can be measured by means of the 
mobility of fluorescence probe as a function of 
temperature.  
In-vitro release: 
 A method of in-vitro release rate study includes the use 
of dialysis tubing. A dialysis sac is washed and soaked in 
distilled water. The vesicle suspension solution is 
pipetted into a bag made up of the tubing and sealed. The 
bag contains the vesicles that are placed in 200ml of 
buffer solution in a 250ml beaker with constant shaking 
at the temperature of 25°C or 37°C. At different time 
intervals, the buffer is analyzed for the drug content by 
an appropriate assay method.  
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Microscopic evaluation:  
Transmission electron microscopy was used for 
microscopic evaluation of niosomal dispersions. TEM 
used for determination of size and used for identified 
whether it is spherical or not. 
Application of Niosomes: 
Niosome as a carrier for hemoglobin: Niosomal suspension 
shows a visible spectrum superimposable onto that of free 
hemoglobin so it can be used as a carrier for hemoglobin. 
Vesicles are also permeable to oxygen and hemoglobin 
dissociation the curve can be modified similarly to non-
encapsulated hemoglobin [1]. 
Niosomes as drug carriers:  
Niosomes have likewise been utilized as transporters for 
iobitridol, asymptomatic operator utilized for X-ray imaging. 
Topical niosomes may fill in as solubilization grid, as a 
neighborhood station for maintained arrival of dermally 
dynamic mixes, as the entrance enhancers, or as rate-
restricting layer obstruction for the tweak of foundational 
ingestion of medications [2]. 
Ophthalmic drug delivery: 
It is difficult to achieve excellent bioavailability of drug from 
ocular dosage forms like an ophthalmic solution, suspension, 
and ointment due to tear production, impermeability of 
corneal epithelium, nonproductive absorption and transient 
residence time. But to achieve good bioavailability of drug 
niosomal vesicular drug delivery systems have been 
proposed [29]. Carter et al. reported that multiple dosing with 
sodium stibogluconate containing niosomes was found to be 
effective against parasites in the liver, spleen and bone 
marrow as compared to simple solution of sodium 
stibogluconate [17, 29]. 
Delivery of peptide drugs 
Yoshida et al investigated the stability of peptide increased 
by niosomes. In Yoshida et al for an oral route for drug   
delivery of 9-desglycinamide, 8-arginine vasopressin 
entrapping in niosomes in an in-vitro intestinal loop model 
and reported that the stability of peptide increased by 
niosomes. [30] 
Transdermal delivery of drugs by niosomes 
In the transdermal route of delivery, when the drug is 
incorporated in niosomes penetration of the drug through 
the skin is enhanced. [30] 
Neoplasia 
The anthracycline antibiotics such as Doxorubicin which 
shows broad-spectrum antitumor activity, produces a dose 
depend an irreversible cardiotoxic effect. This drug 
increased the lifespan and decreased the rate of proliferation 
of sarcoma when administered by niosomal delivery into 
mice bearing S-180 tumor. [30] 
Use in studying immune response: [32] 
Because of their immunological selectivity, low danger and 
more noteworthy solidness; niosomes are being utilized to 
ponder the idea of the insusceptible reaction incited by 
antigens. Nonionic surfactant vesicles have plainly exhibited 
their capacity to work as adjuvant after parenteral 
organization with various distinctive antigens and peptides. 
Anti-inflammatory agents [31] 
Niosomal formulation of Diclofenac sodium with70% 
cholesterol exhibits greater anti-inflammatory activity as 
compared to free drug. Niosomal formulation of Nimesulide 
and Flurbiprofen shows greater anti-inflammatory activity as 
compared to free drug. Sharma et al (2009) were developed 
span-60 niosomal oral suspension of fluconazole in the 
treatment of fungal infection. It is effective as compare to 
capsule and tablets. [33] 
Leishmaniasis [12, 34, 35] 
Niosomes can be utilized for focusing on medication in the 
treatment of maladies in which the contaminating life form 
lives in the organ of the reticuloendothelial framework. 
Leishmaniasis is such an infection in which parasite attacks 
cells of liver and spleen. 
Immunological application [12] 
Niosomes have been also used for studying the nature of the 
immune response provoked by antigens. Brewer and 
Alexander have reported niosomes as a potent adjuvant in 
terms of immunological selectivity, low toxicity and stability. 
Niosomes in gene delivery [20] 
Novel niosome detailing in light of the 2, 3-di (tetra-decyl-
oxy) propan-1-amine cationic lipid, joining with squalene 
and polysorbate 80 to assess the transfection productivity in 
rodent retinas. Lipoplexes at 15/1 proportion was 200 nm in 
a measure, 25mV in zeta potential and displayed circular 
morphology. At this proportion, it was seen that niosomes 
consolidated and secured the DNA from enzymatic 
processing. 
Tetanus toxoid (TT) [20, 36]  
Yoshika et al defined Span/CHOL/DCP niosomes containing 
lockjaw toxoid which was a vesicle-in water-in oil 
framework. Cottonseed oil was utilized and gave better 
immunological properties when contrasted with free 
antigen. Katare et al (2006) developed the polysaccharide-
capped niosomes for oral immunization of tetanus toxoid 
and he was concluded that the niosomes were good 
approaches for oral immunization of tetanus toxoid.  
Diagnostic imaging with niosomes Niosomal framework can 
be utilized as demonstrative operators. Conjugated niosomal 
with N-palmitoylglucosamine (NPG), PEG 4400 and both PEG 
and NPG display essentially enhanced tumor focusing of an 
evaluated paramagnetic specialist evaluated with MR 
imaging. [37]  
Wagh et al (2012), was developed itraconazole niosomes 
drug delivery system and study its antimycotic against 
Candida albicans. He was enhanced the skin permeability of 
itraconazole by niosomal drug delivery. [34] 
 
Srivastav et al (2014) was developed the niosomes of 
ofloxacin and study its antimicrobial activity. He was 
prepared ofloxacin niosomes by using ether injection method 
[38].  
Mishra et al (2014) was developed the formulation of 
Niosomes of Aceclofenac used as NSAID [39].  
Bayindir et al (2010) was developed niosomes prepared with 
various nonionic surfactants for paclitaxel oral delivery. 
Paclitaxel is an antineoplastic agent. Paclitaxel niosomal 
formulation was prepared by various surfactants such as 
Tween 20, 60, Span 20, 40, 60, Brij 76, 78, 72 by film 
hydration method [40]. 
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CONCLUSION 
Drug consolidations in the niosomes to focus around the 
niosomes are a specific site that is a promising drug delivery 
model. They show a structure like a liposome and 
consequently, they can speak to elective vesicular 
frameworks as for liposomes, due to the niosome capacity to 
exemplify a distinctive sort of medications inside their multi 
environmental structure and furthermore because of 
different elements like cost, stability and so on. These 
advantages over the liposomes make it a better targeting 
agent. Ophthalmic, topical, parenteral and various other 
routes are used for targeting the drug to the site of action for 
better efficacy. 
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